New shuttle session with our in vivo syngeneic tumor models for cost-saving efficacy studies
07 / 16 / 2019
Figure 1: Subcutaneously-implanted MCA205 sarcoma and 4T1 breast tumor-bearing mouse models are differentially sensitive to PDL1 blockade. Mice were subcutaneously implanted with respective tumor cells and exposed to anti-PDL1 antibody. Tumor growth was monitored overtime via calipering. Tumor volume and survival were then determined. The two tumor models exhibit differential responsiveness levels ; MCA205 being strongly responsive while 4T1 model is only very slightly sensitive.
Figure 2: Differential responses of the subcutaneously-implanted CT26 colon tumor-bearing mouse model to immune checkpoint inhibitors and chemotherapy. A. Mice were challenged with CT26 tumor cells and exposed to either anti-CTLA4, anti-PD1 or anti-PDL1 antibodies, or to 5FU treatment. Contrarily to the strong response to anti-CTLA4 antibody, CT26 tumor is partially responsive to PD1/PDL-1 blockade. A partial response is also observed upon 5FU treatment. B. Mice were challenged with CT26 tumor cells and exposed to anti-PDL1 antibody and a small molecule drug, each alone and in combination. Tumor growth was monitored overtime via calipering. Tumor volume and survival were then determined. Responsiveness of CT26-tumor bearing mice to PDL1 blockade is optimized when combined with the small molecule drug.
Shuttle for efficacy assessment on 6-week experimental session
- Model / Strain: According to the Sponsor's requirements
- Readouts: Tumor growth / Body weight / Survival
- Standard reference: Immune checkpoint inhibitor – to be discussed with the Sponsor
- Group size: At least 10 mice per group